Literature DB >> 2890967

Lysis of basilar artery occlusion with tissue plasminogen activator.

T Henze, A Boeer, U Tebbe, J Romatowski.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2890967     DOI: 10.1016/s0140-6736(87)91275-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.

Authors:  D T Cross; C P Derdeyn; C J Moran
Journal:  AJNR Am J Neuroradiol       Date:  2001-03       Impact factor: 3.825

Review 2.  Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial.

Authors:  L Candelise; C Roncaglioni; E Aritzu; A Ciccone; A P Maggioni
Journal:  Ital J Neurol Sci       Date:  1996-02

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

4.  Heralding manifestations of basilar artery occlusion with lethal or severe stroke.

Authors:  G von Campe; F Regli; J Bogousslavsky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-12       Impact factor: 10.154

5.  Recombinant tissue plasminogen activator in two patients with basilar artery occlusion.

Authors:  D Herderscheê; M Limburg; A Hijdra; P A Koster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

6.  Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke.

Authors:  P J Koudstaal; J Stibbe; M Vermeulen
Journal:  BMJ       Date:  1988-12-17

Review 7.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.